Compare HCA Health Inc (HCA) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs KLA Corp. — how do they compare? HCA Health Inc trades at $446.54 (market cap $96.35B), while KLA Corp. trades at $195.83 (market cap $256.72B). The key difference: KLA Corp. is far larger — about 2.7× HCA Health Inc's market cap, and HCA Health Inc pays the higher dividend (0.7%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and KLA Corp. for 60 Days on average.
| HCA | KLAC | |
|---|---|---|
Market Cap | $96.35B | $256.72B |
Volume | 1,079,453 | 9,970,753 |
Sector | Health | Technology |
52-Week High | $545.13 | $301.71 |
52-Week Low | $361.32 | $98.28 |
Typical Hold Time | 76 Days | 60 Days |
Enterprise Value | $146.88B | $257.97B |
Dividend Yield | 0.7% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.
The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.
KLA Corporation (KLAC) trades at $196.83, down 0.32% on the day, with strong technical support at $194 and resistance at $198. The company demonstrates robust fundamentals with revenue growth from $9.8B in 2024 to $12.16B in 2025 and net income margin expanding to 35.57%. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.05 surpassing the $1.00 estimate. AI-driven demand is fueling backlog growth to $12.57B, positioning KLAC for continued expansion in semiconductor equipment markets.
KLAC presents a compelling growth opportunity with strong analyst support (28 buys vs 2 sells) and a $223.88 consensus price target offering 14% upside. However, elevated valuation ratios (P/E 53.75, P/S 19.12) and competitive pressures from Applied Materials and ASML represent key risks. The stock's technical bullish signal and institutional accumulation support near-term momentum, though margin compression and semiconductor cycle volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
